what is glp-1 ra Receptor Agonists and Research to Treat Overeating and Substance Use Disorders Trends in the Development of

Scott Harris, M.D., will be discussing the promise of #GLP1/#Glucagon approaches in treating #MASH and #MASLD, as well as the importance of developing therapies tailored to the specific needs of patients with #obesity and/or #MASH

A consensus clinical practice recommendation endorsed by the Australian Diabetes Society (ADS), National Association of Clinical Obesity Services (NACOS), Gastroenterological Society of Australia (GESA) and Australian and New Zealand College []

From gluten-free to Whole30, food labels have always reflected the health trends of their time

In the past two years, Ive spent time assessing and working with and through the phenomenon of GLP-1s in health care through the consumer lens and how this category of prescription drugs are profoundly impacting many segments of the U.S

Early experience

GMA105 is a fusion protein that combines GLP-1 fragments with a humanized monoclonal antibody against GLP-1R, while GMA106 includes an antagonistic GIPR antibody fused with GLP-1 molecules, achieving dual receptor activation